Abstract
Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Harris WS, von Schacky C: The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 2004, 39:212–220.
• Hlatky MA, Greenland P, Arnett DK, et al.: Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119: 2408–2416. This important paper provides a roadmap and rationale for the evaluation and validation of new markers for CHD.
Hill AB: The environment and disease: association or causation? Proc R Soc Med 1965, 58:295–300.
Harris WS: The omega-3 index: from biomarker to risk marker to risk factor. Curr Atheroscler Rep 2009, 11:411–417.
Siscovick DS, Raghunathan TE, King I, et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J Am Med Assoc 1995, 274:1363–1367.
Albert CM, Campos H, Stampfer MJ, et al.: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113–1118.
Block RC, Harris WS, Reid KJ, et al.: EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2007, 197:821–828.
Hamazaki K, Terashima Y, Itomura M, et al.: The relationship between n-3 long-chain polyunsaturated fatty acids and pulse wave velocity in diabetic and non-diabetic patients under long-term hemodialysis. A horizontal study. Clin Nephrol 2009, 71:508–513.
Itomura M, Fujioka S, Hamazaki K, et al.: Factors influencing EPA+DHA levels in red blood cells in Japan. In Vivo 2008, 22:131–135.
Ogura T, Takada H, Okuno M, et al.: Fatty acid composition of plasma, erythrocytes and adipose: their correlations and effects of age and sex. Lipids 2010, 45:137–144.
Sekikawa A, Curb JD, Ueshima H, El Saed A, et al.: Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008, 52:417–424.
Harris WS: The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 2008, 87:1997S–2002S.
Park Y, Lim J, Lee J, Kim SG: Erythrocyte fatty acid profiles can predict acute non-fatal myocardial infarction. Br J Nutr 2009, 102:1355–1361.
Yokoyama M, Origasa H, Matsuzaki M, et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090–1098.
GISSI-HF investigators, Tavazzi L, Maggioni AP, et al.: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223–1230.
Marchioli R, Barzi F, Bomba E, et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897–1903.
Di Stasi D, Bernasconi R, Marchioli R, et al.: Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol 2004, 60:183–190.
• Metcalf RG, Cleland LG, Gibson RA, et al.: Relation between blood and atrial fatty acids in patients undergoing cardiac bypass surgery. Am J Clin Nutr 2010, 91:528–534. RBC EPA+DHA levels were shown to correlate highly with human myocardial EPA+DHA content, indicating that the former is a valid surrogate marker for the latter.
Larson MK, Ashmore JH, Harris KA, et al.: Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008, 100:634–641.
Carney RM, Freedland KE, Rubin EH, et al.: Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009, 302:1651–1657.
Harris WS, Lemke SL, Hansen SN, et al.: Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids 2008, 43:805–811.
Block RC, Harris WS, Pottala JV: Determinants of blood cell omega-3 fatty acid content. Open Biomark J 2008, 1:1–6.
Katan MB, Deslypere JP, van Birgelen AP, et al.: Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997, 38:2012–2022.
• Harris WS, Thomas RM: Biological variability of blood omega-3 biomarkers. Clin Biochem 2009, 43:338–340. The within-person stability of the Omega-3 Index, total plasma, and plasma phospholipid EPA+DHA was assessed in 20 volunteers tested weekly for 6 weeks. The variability of the Omega-3 Index was about one third of that of the other two markers.
•• Farzaneh-Far R, Lin J, Epel ES, et al.: Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010, 303:250–257. This is the first study to describe an inverse association between blood levels of EPA+DHA and the rate of “cellular aging.” The latter was assessed by measuring the change in leukocyte telomere length in over 600 patients with stable CHD over a 5-year period of time.
Ali S, Garg SK, Cohen BE, et al.: Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: data from the Heart and Soul Study. Psychother Psychosom 2009, 78:125–127.
Aarsetoy H, Ponitz V, Nilsen OB, et al.: Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008, 78:258–264.
Kohler A, Bittner D, Low A, von Schacky C: Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br J Nutr 2010 Apr 27:1–8 [Epub ahead of print].
Bang HO, Dyerberg J: Lipid metabolism and ischemic heart disease in Greenland eskimos. Adv Nutr Res 1980, 3:1–22.
Disclosure
Dr. William S. Harris is a consultant to several companies with interests in omega-3 fatty acids including GlaxoSmithKline, Acasti Pharma, Omthera, and Monsanto. He was a speaker for the former. In 2009 he founded and is President of OmegaQuant, LLC, a company that offers Omega-3 Index testing.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harris, W.S. The Omega-3 Index: Clinical Utility for Therapeutic Intervention. Curr Cardiol Rep 12, 503–508 (2010). https://doi.org/10.1007/s11886-010-0141-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11886-010-0141-6